Phase I Open Label, Multi-center, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma or Multiple Myeloma

Trial Profile

Phase I Open Label, Multi-center, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma or Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Fimepinostat (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Curis
  • Most Recent Events

    • 08 Mar 2018 According to a Curis media release, combined analysis of the Phase 1 and Phase 2 trial results of CUDC-907 in patients with relapsed/refractory DLBLC presented at the American Society of Hematology's annual meeting.
    • 01 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Dec 2018.
    • 01 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top